Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Deal or No deal

<< Previous

Bullboard Posts

Next >>

Comment by houbahopon Mar 12, 2023 7:45pm

98 Views

Post# 35333787

RE:RE:Deal or No deal

This scenario was easily predictable and it is a clear proof investors never showed up to buy the stock. We know now why TH traded so cheaply since the end of 2021. Now that the news is out in the papers, it is to late to sell and save your skin.

Good luck to all who stayed on the sinking ship.
In the next couple of months, management will play all the available cards to convince to stay.

It will be interesting to see the turn out of the votes at the next AGM.

<< Previous

Bullboard Posts

Next >>

Osisko Development receives permits for Cariboo Gold Project